Annual Drug Patent Expirations for COMETRIQ
Cometriq is a drug marketed by Exelixis and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.
Drug patent litigation for COMETRIQ.
This drug has one hundred and forty-three patent family members in twenty-nine countries.
The generic ingredient in COMETRIQ is cabozantinib s-malate. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
